Results 231 to 240 of about 7,267,381 (385)

Microglial reprogramming: a potential new frontier in enhancing immunotherapy for melanoma brain metastasis

open access: yesMolecular Oncology, EarlyView.
Microglia act as tumor suppressors during brain metastasis colonization but shift to a tumor‐promoting role after melanoma brain metastases form. NF‐κB/RelA signaling emerges as a key driver of this phenotypic shift. Targeting this pathway reprograms microglia into a pro‐inflammatory state, enhancing antitumor immunity and immune checkpoint inhibitor ...
Noam Savion‐Gaiger   +2 more
wiley   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

open access: yesMolecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani   +14 more
wiley   +1 more source

Molecular HDD logic for encrypted massive data storage. [PDF]

open access: yesNat Commun
Guo B   +13 more
europepmc   +1 more source

The conducting system of the vertebrate heart [PDF]

open access: green, 1943
Valentino Chiodi, R. Bortolami
openalex   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

open access: yesMolecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Rules of Connectivity-Dependent Phonon Interference in Molecular Junctions. [PDF]

open access: yesNano Lett
Zheng L   +4 more
europepmc   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

open access: yesMolecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy